Introduction: Pharmacotherapy and counseling for tobacco cessation are evidence-based methods that increase successful smoking cessation attempts. Medicaid programs are required to provide coverage for smoking cessation services. Monitoring utilization is desirable for program evaluation and quality improvement. Various methodologies have been used to study utilization. Many factors can influence results, perhaps none more than how smokers are identified. This study evaluated the utilization of smoking cessation services using various methods to estimate the number of smokers within New York State's (NYS's) Medicaid program in 2015. Methods: Estimates of utilization were generated based on Medicaid claims and encounters and four sources of smoking prevalence: two population surveys, one Medicaid enrollee survey, and diagnosis codes. We compared the percentage of (estimated) smokers utilizing cessation services, and the average number of services used, across fee-for-service and managed care populations, and by cessation service category. Results: Statewide, smoking prevalence estimates ranged from 10.9% to 31.5%. Diagnosis codes identified less than 45% of smokers estimated by surveys. A similar number of cessation counseling (199 106) and pharmacotherapy services (197 728) were used, yet more members utilized counseling (126 839) than pharmacotherapy (91 433). The estimated percentage of smokers who used smoking cessation services ranged from 15.1% to 43.4%, and the estimated average number of cessation services used ranged from 0.31 to 0.90 per smoker. Conclusion: Smoking prevalence estimates obtained through surveys greatly exceed prevalence observed in diagnosis codes in NYS's Medicaid data. Use of diagnosis codes in the analysis of smoking cessation benefit utilization may result in overestimates. Implications: Selection of a smoking prevalence data source for similar analyses should ultimately be based on completeness of the data and applicability to the population of interest. Evaluation of smoking cessation benefit utilization and the effectiveness of tobacco control campaigns aimed to increase utilization requires a well-defined methodology which ensures reliable baseline data. Comparing utilization estimates across populations or state lines can be misleading, as differences in how estimations were generated can greatly bias observed results.
Introduction
Smoking remains the largest contributor to preventable disease and death in the United States. 1 Medicaid recipients have a higher prevalence of smoking than commercially insured individuals and are considered a priority population for tobacco control interventions in New York State (NYS). 2 Current NYS Medicaid enrollment exceeds 6 million people, with nearly 80% in Medicaid managed care (MMC). 3 Current Federal health law requires health insurers to cover smoking cessation treatments for all adult enrollees at no cost. Specific benefits and requirements to obtain the services vary by insurer and state, across Medicaid fee-for-service (FFS) and MMC delivery systems. 4 Increasingly, smoking cessation benefit utilization (SCBU) is being estimated to measure progress in increasing provision of evidence-based treatments, provide evidence of opportunities for improvement, and to study the relationship between service utilization and smoking prevalence. These estimates vary widely, largely due to the methods used to compute them, the degree to which states promote benefits, and other factors noted below. Analysis of the 2000 National Health Interview Survey (NHIS) found that 15.5% of Medicaid self-identified smokers reported use of a cessation aid in a quit attempt. 5 In an evaluation of the impact of mandating smoking cessation coverage provided through the Massachusetts Medicaid program (MassHealth), it was reported that between 2006 and 2008 as many as 37% of smokers, utilized smoking cessation benefits. 6 Subsequently, the Massachusetts Department of Health reported that the percentage of smokers utilizing pharmacotherapy had risen to 44.8% between 2007 and 2010, with 2.3% of smokers utilizing cessation counseling. 7 Last year, a study looking at the utilization of smoking cessation medications in Medicaid programs nationally, estimated that only 10% of Medicaid smokers had utilized smoking cessation pharmacotherapy in 2013, with significant variation across states. 8 Interestingly, this study estimated MassHealth pharmacotherapy smoking cessation to have occurred in only 35% of smokers. For New York State, the estimate was 24%. The study did not look at the utilization of smoking cessation counseling, citing that medications have been found to be the primary form of therapy used.
Variation in reported SCBU across different studies is not surprising. It is critical to consider the many factors that affect the quantification of SCBU before calculating state-specific SCBU, evaluating performance, developing utilization targets, changing messages in smoking cessation campaigns, or adjusting state-specific Medicaid smoking cessation benefit packages. Measuring the utilization of services in any population requires a percentage or rate, as crude counts of services do not account for changes in the underlying population sizes. Researchers need to consider continuous enrollment criteria, administrative changes in the program such as expanded healthcare (Medicaid) coverage or the carve-in of new populations, health plan mergers and acquisitions, and other factors affecting the population. Further, quantifying the prevalence of smoking is challenging, as it requires either a documented diagnosis, or individual self-report.
The purpose of this paper is to present SCBU analysis conducted using NYS Medicaid data, to illustrate and discuss the impact that the methodology, specifically the selection of smoking prevalence data, can have on generating Medicaid program specific SCBU. We present four distinct SCBU percentages and the average number of treatments per utilizer, estimated using four different sources of smoking prevalence data (two population-based surveys, one survey of Medicaid enrollees, and Medicaid claims data).
Methodology
We estimated SCBU in six steps: (1) calculate Medicaid enrollment, (2) choose a source for the smoking prevalence estimate and extrapolate estimated number of smokers in Medicaid, (3) count smoking cessation services utilized during the year, (4) count distinct eligible members utilizing smoking cessation services, (5) calculate the average number of services utilized per the estimated number of smokers, and (6) calculate the estimated percentage of distinct smokers utilizing smoking cessation services (by dividing actual service utilization by the estimated number of smokers). Using these steps, we generated SCBU estimates at the Medicaid statewide level, within MMC, and within FFS. Within each of these populations, we generated a distinct SCBU estimate based on each available source of smoking prevalence data for that population. Counts of enrollment, prevalence, and utilization events for each program and region were all restricted to distinct adult (18-64 years of age) enrollees who were not dually enrolled in both Medicaid and Medicare (non-duals) in 2015. The resulting estimates of SCBU were then compared within and across populations.
In the first step, Medicaid enrollment was calculated statewide and within the FFS and the MMC programs for all non-dual adults aged 18-64 years. A member was counted once for each program in which they received services during the calendar year. Thus, some individuals were counted in both FFS and MMC independently, but only once in the statewide total. Continuous enrollment criteria were not applied, which means that the members did not have to be continuously enrolled in Medicaid during the year.
Four data sources were used to quantify smoking prevalence: 1) the New York State Behavioral Risk Factor Surveillance System (BRFSS), 2) the New York State Adult Tobacco Survey (ATS), 3) the Managed Care Consumer Assessment of Healthcare Providers and Systems (CAHPS), and 4) Medicaid claims and encounter data (diagnosis codes). Each data source is described in detail below.
BRFSS Data
New York State's BRFSS is an annual statewide telephone (landline and cell phone) surveillance system designed by the Centers for Disease Control and Prevention (CDC). 9 New York State's BRFSS sample represents the noninstitutionalized adult population, aged 18 years and older. The survey is conducted in all 50 states and US territories, with a common core component, optional modules, and state-added questions, fielded continually during the year. Since 2013, NYS BRFSS asks respondents, "what is the primary source of your health care coverage?". The current analysis used data collected in the 2015 NYS BRFSS, which had a response rate of 35.8%. To measure smoking status, respondents were classified as smokers if they respond "yes" to having smoked at least 100 cigarettes in his/ her entire life, and reported that they now smoke "every day" or "some days." BRFSS data undergo an iterative proportional fitting, or raking, process to weight the data. The BRFSS raking includes categories of age by gender, detailed race and ethnicity groups, education levels, marital status, regions within states, gender by race and ethnicity, telephone source, renter or owner status, and age groups by race and ethnicity. 10 Respondents 65 years or older are excluded from the Medicaid smoking prevalence estimate. Consistent with the BRFSS, respondents were classified as smokers if they respond "yes" to having smoked at least 100 cigarettes in his/ her entire life, and report that they now smoke "every day" or "some days." Sample weights are created independently for the landline sample and for the cellphone sample up to the stage of poststratification. Sampling weights account for the probability of selection, nonresponse, household size, and number of telephone lines. Finally, the weights are poststratified to reflect population totals based on combinations of age, race/ethnicity, gender, and geographical region.
ATS Data
Respondents 65 years or older are excluded from the Medicaid smoking prevalence estimate.
CAHPS® Data
The adult CAHPS® survey is a Medicaid member satisfaction survey. 12 In NYS, it is conducted every other year, administered to a random sample of 1500 adults from each MMC plan, using a combined mail and phone methodology (telephonic follow-up is only conducted for nonresponders to the mailed survey). A plan's eligible population is comprised of all adult members (18-64 years old) continuously enrolled in the plan for 5 of the first 6 months of a survey year. CAHPS® survey results are reported separately for each plan without adjustment for characteristics of the responding subset of the random sample. The current analysis used data collected in 2015. The statewide response rate of the 2015 adult CAHPS approached 30%. To measure smoking status, respondents were classified as smokers if they reported that they "now smoke cigarettes or use tobacco every day, some days, or not at all." Plan specific results were combined and weighted by enrollment to obtain statewide estimates, accounting for varied smoking prevalence across regions of the state and variability in regional response rates to the surveys.
Medicaid Claims and Encounters Data (Diagnosis Codes)
Data on medical service utilization is submitted through eMedNY, for adjudicated, and ultimately stored in NYS's Medicaid Data Warehouse as a claim for reimbursement (from providers serving the FFS population) or as an encounter (from a managed care plan). Each individual submission includes information on who received the service, who provided the service, what the service was, where it was provided, when it was provided, the cost, and diagnoses. Diagnoses are submitted using the International Classification of Disease Codes (ICD). Smokers were identified in claims and encounters submitted in 2015, using any diagnosis with ICD-9 or ICD-10 codes (ICD-9 code 305. .298, and F12.299). The Medicaid program also tracks enrollment on a monthly basis, with a distinct record that for each month a member was enrolled, providing updated eligibility, enrollment status, and demographic information. In the current analysis, we identified all claims and encounters with these diagnosis for non-dual adult Medicaid enrollees aged 18-64 years old.
Neither the BRFSS nor the ATS ask if those who reported Medicaid coverage are enrolled in MMC or FFS; therefore, we cannot estimate distinct MMC and FFS prevalence. Conversely, the CAHPS survey is MMC specific, and therefore does not allow for Medicaid-wide estimates of prevalence. For these reasons, Medicaid FFS smoking prevalence can currently only be derived based on diagnosis codes in claims and encounters.
In the second step, smoking prevalence estimates derived from the three surveys were applied to the enrollment numbers calculated in step one to generate estimates of the number of adult smokers in Medicaid. For analyses based on diagnosis codes, the number of smokers was determined directly from the count of applicable diagnoses. The resulting estimated number of smokers from each data source served as the denominators in our analysis.
In the third step, claims and encounter data from 2015 for smoking cessation pharmacotherapy or counseling were compiled. National Drug Codes (NDC) were used to identify pharmacotherapy. The identification of applicable NDC codes was based on drug therapeutic codes 72142, 72143, 72144, 72145, 72147, 72148, and 72149, or categorization of the drug as being a "smoking deterrent." Bupropion, due to its use as both a smoking cessation agent and an antidepressant, was excluded from analyses, except for cases in which the drug's therapeutic code explicitly indicated that its use was for smoking cessation. Any product with a therapeutic class code of U6W (Bulk Chemicals) was also excluded, as these are not used in the clinical setting. In total, 1387 NDC codes were identified and utilized in this analysis.
NYS's Medicaid program currently provides reimbursement for smoking cessation counseling services provided and documented using Current Procedural Terminology (CPT) codes 99406, 99407, and D1320 corresponding to smoking cessation counseling lasting 3 to 10 min, lasting greater than 10 min, and counseling conducted in a dental setting, respectively. The CPTII code 4000F, and Healthcare Common Procedure Coding System (HCPCS) codes G0436, G0437, and S9453 were additionally included in this analysis, as these codes were observed to be used, albeit on a limited basis and primarily in encounter data. CPTII code 4000F identifies smoking cessation counseling administered for those with specific underlying comorbidities including COPD, asthma, and diabetes. HCPCS codes G0436, G0437, and S9453 correspond to smoking cessation counseling lasting 3 to 10 min, lasting more than 10 min, and counseling conducted in a nonphysician provider class, respectively. CPTII code 4001F was not included as it represents a pharmacotherapy event, not counseling. CPTII code 4004F was also excluded as it does not specify which type of intervention was provided.
To complete steps four and five, the total number of smoking cessation services obtained by non-dual adult Medicaid enrollees were summed, and members utilizing these services counted, stratifying the by treatment type (pharmacotherapy, counseling, or a combination of both), within each Medicaid population (statewide, MMC, or FFS). Counts of smokers utilizing smoking cessation services were then divided by the estimated number of non-dual adult smokers to obtain SCBU percentages. Finally, in step six, the average number of services utilized per smoker was then calculated, by dividing the total count of services utilized by the estimated number of smokers from a given source, stratified by service type, and population.
Results
Enrollment and smoking prevalence data are presented in Table 1 . The number of non-dual adult Medicaid members 18 to 64 years old in NYS in 2015 was 4 012 335. Of those members, the vast majority (85.9%) were in the MMC program. Across all populations (statewide, MMC, and FFS), estimates of smoking prevalence obtained from surveys (range 21.2%-31.5%) were consistently higher than prevalence derived from diagnosis codes (range 4.7%-11.1%). The smoking prevalence estimate for the MMC population (21.2%, based on CAHPS data) was lower than statewide estimates obtained from BRFSS and ATS (25.9% and 31.5%, respectively). Smoking prevalence in the FFS population (based on diagnosis codes) was 4.7%. The counts of smokers identified with diagnosis codes, and those extrapolated based on enrollment and smoking prevalence estimates, across each Medicaid population, are also presented in the table.
Counts of smoking cessation service utilization events and distinct members utilizing these services are presented in Table 2 . Statewide, 396 834 smoking cessation services were used, of which 92.1% occurred among the MMC population. The number of smoking cessation counseling and pharmacotherapy treatments provided statewide was very similar (199 106 compared to 197 728, respectively). The count of distinct qualifying members utilizing smoking cessation services was 190 673. Statewide, cessation counseling services were utilized by more distinct members (n = 126 839) compared with pharmacotherapy interventions (n = 91,433). A similar pattern was observed at the MMC and FFS level of analysis, with 1791 more FFS members utilizing counseling benefits versus pharmacotherapy, and 33 319 more MMC members utilizing counseling over pharmacotherapy. Though not presented, it is worth mentioning that over 83% of all cessation counseling events were for counseling lasting 3 to 10 min. The more intensive cessation counseling, lasting over 10 min in a group or individual session, occurred more often in the MMC population than the FFS population (17.1% versus 14.5%, respectively, p < .01). Fewer members utilized a combination of both services during the year across both FFS and MMC (n = 27 599), the majority occurring within the MMC population (n = 25 949 versus n = 2440 among FFS).
Based on these numbers, we estimate that statewide, in 2015, between 0.31 and 0.90 events were utilized per non-dual adult NYS Medicaid smoker, split approximately evenly between pharmacotherapy and counseling. When smoking prevalence was based on the BRFSS data, the average number of cessation events utilized per Medicaid smoker was slightly higher than that when using the ATS data (0.38 and 0.31, respectively). The highest estimates of average service use per smoker was seen within the MMC population, regardless of if smoking prevalence was obtained from diagnosis codes (0.96 events) or survey data (0.50 events; Table 3 ).
Overall, we estimated that between 15.1% to 43.4% of non-dual adult Medicaid smokers utilized smoking cessation services in NYS, in 2015. Utilization of these services was found to be higher in the MMC population than in the FFS population (MMC range 24.1%-46.2%, FFS = 22.9%), with the highest estimates based on smoking prevalence obtained from diagnosis codes. (Table 4) .
Discussion
Recognizing the impact of various methodological approaches to calculate SCBU will ultimately allow for better understanding of the effectiveness of benefit promotion by state Medicaid programs like paid media campaigns. How qualified enrollment was defined, which data sources were used for smoking prevalence estimates, and how smoking cessation service events were identified and counted will have critical implications on estimated SCBU. The results of the current analysis demonstrate the impact of changing the source of smoking prevalence data. When diagnosis codes were used to calculate smoking prevalence in the calculations of SCBU, the results suggested that smoking cessation services were being used by almost half of the smokers in the MMC program and over 40% of smokers Medicaid wide. This is driven by the decrease in the number of smokers (denominator) calculated using the diagnosis codes. Using prevalence estimates from any of the three surveys resulted in much larger estimated number of smokers (denominators), and subsequently more moderate estimates of SCBU.
Variability in smoking prevalence estimates across surveys was probably driven by differences in how the surveys were administered, sampling methodology, and response rates. The CAHPS estimate was slightly lower than BRFSS and ATS estimates, though it is unclear if this difference is driven by a difference in smoking prevalence in the MMC population, or in survey bias. Regardless, estimates derived from survey methods were more than 1.9 times higher than that evident in the diagnosis codes.
It is worth noting that both surveys require self-report of insurance status, which is known to have measurement error with the general population often underreporting Medicaid enrollment. 13 The accuracy of reported insurance status will likely vary state by state and between various surveys. Researchers choosing to use survey data should recognize this as a potential limitation.
In the current study, the fact that all three survey estimates of smoking prevalence approximated national estimates suggests that diagnosis codes underestimate smoking prevalence in the NYS Medicaid population. This is logical, as it should not be expected that all current smokers encountered the health care system during 2015, nor would they necessarily be diagnosed at all points of contact. Physicians may not document a diagnosis of smoking in smokers who have been previously diagnosed or when they are not actively providing treatment. Diagnosis may very well be dependent on the writing of a script for a cessation service; the current study did not investigate the co-occurrence of diagnosis and cessation service. Documentation of smoking behavior may still be present in the patient's medical record, but these data are not administratively available. Regardless, diagnosis codes will never reflect information on those enrollees who did not see a clinician, and as such will always underestimate prevalence and overestimate SCBU. Encouraging that routine clinical documentation of smoking status among the official diagnoses in medical records is advisable, as other sources of smoking prevalence rarely identify individual members who could benefit from member level outreach.
The inclusion of withdrawal and remission codes in the analysis was based on the logic that these codes would likely only be applicable to individuals who were smokers during the evaluation period. Furthermore, individuals in withdrawal or remission could potentially be high utilizers of smoking cessation services during the year. Withdrawal and remission codes only accounted for 0.19% of diagnosed cases, and we did not include those individuals whose sole (tobacco use) diagnosis was a "history of tobacco dependence" (ICD9 V15.82, ICD10 Z87.891).
In light of our findings, and for several notable reasons, NYS has decided to use the smoking prevalence derived from the BRFSS data for analyses of SCBU in the statewide Medicaid program, and CAHPS data for analysis of SCBU in the MMC program. We selected the BRFSS over the ATS because of the larger sample size (greater confidence in estimates), history of continued administration in NYS (since 1985), stability of smoking prevalence estimates over time, and the fact that it is conducted in every state and supported by the CDC. The absence of information on Medicaid care model (MMC versus FFS) in the BRFSS data necessitated the use of the CAHPS data to estimate MMC specific smoking prevalence and SCBU. Furthermore, the use of CAHPS data in MMC analysis allows stratification by MMC plan. The state currently publishes a MMC plan SCBU report, trending 5 years of plan specific performance, updated yearly, on our Medicaid Managed Care Reports website. 14 As described in the methodology, we decided not to apply continuous enrollment criteria to any of the components of this analysis, as it necessitates omission of cessation services obtained by those not continuously enrolled. This decision was made despite the fact that CAHPS sampling is based on a continuously enrolled population. In some instances, continuous enrollment criteria are desirable, such as when producing MMC plan specific reports. When continuous enrollment criteria are used, it is important to consider the representativeness of the continuously enrolled population relative to the full population. Should the selected source of smoking prevalence data incorporate continuous enrollment criteria in developing the sample frame, researchers will also need to decide whether or not to use continuous enrollment criteria in defining the base population. In any case, the numerator events should only be counted among those individuals who would qualify for the base population.
Another factor to consider is any administrative or policy changes to the Medicaid program during the period of analysis, such as movement of new populations from FFS into MMC, or plan mergers and acquisitions. The incoming population may have very different smoking prevalence or SCBU than the previous population. This may create problems in trending data over time, and should always be considered when evaluating the appropriateness of using a given estimate of smoking prevalence for combined population.
The current study had several limitations. In estimating smoking prevalence, our use of diagnosis codes required the diagnosis to have occurred in the current year, as a proxy for current smoking. The transition from ICD9 to ICD10 in the third quarter of 2015 could have resulted in coding errors, though quarterly analysis of smoking diagnosis from 2014 through 2017 in NYS Medicaid data revealed no reason for concern, and the 2015 data are widely used by the department. As previously discussed, BRFSS and ATS in New York State may underreport Medicaid participation, which would likely underestimate smoking prevalence, as smoking is known to be more prevalent in Medicaid than the general population. The CAHPS smoking prevalence estimate could have been inflated by nonsmoking tobacco users (based on the survey language, which differed from the BRFSS and ATS), though this subset of tobacco users is estimated to represent less than 2% of the Medicaid population. 15 Regarding our evaluation of smoking cessation service utilization, pharmacotherapy for smoking cessation that involved offlabel use of bupropion products classified antidepressants would have been missed. However, including bupropion without restriction resulted in a 194% increase (unpresented analysis) in cessation utilization counts, the vast majority of which would not have been associated with smoking cessation. The current analysis would also have missed any discussions of smoking cessation that occurred in a physician's office, or in the dental setting, that did not meet NYS Medicaid's definition of an approved, billable, counseling session. Furthermore, any prescription for a pharmacotherapy that was not ultimately filled would have been missed, as would the use of any over the counter product that was not submitted for reimbursement. Likewise, we were not able to account for any instance in which a prior-authorization requirement (which in 2015 varied by MMC plan) prevented a cessation service from being obtained. Finally, we were not able to exclude any pharmacotherapy or counseling that was used for nonsmoking tobacco cessation.
Inherent differences in the design of state Medicaid programs (specifically benefit packages and care-delivery models) and the characteristics of underlying populations will undoubtedly affect the ability of tobacco control programs to increase smoking quit attempts through encouraging the utilization of available cessation services. Comparing the relative success of state programs in increasing SCBU can provide insight into what may be a successful strategy to increase smoking quit attempts. However, even if the comparison methodology is standardized, the data sources used to estimate smoking prevalence could have varied reliability across state lines, and interpretation of calculated SCBU performance should be cautioned. Furthermore, baseline smoking prevalence should always be considered when comparing SCBU across populations. According to a recent MMWR, NYS was seen to have the second lowest Medicaid smoking prevalence among Medicaid expansion states. 16 The population that continues to smoke cigarettes in NYS Medicaid is likely the most reluctant to quit and hardest to reach.
Increasing quit attempts and decreasing smoking prevalence in NYS' Medicaid population continues to be a public health priority for the state Department of Health. Progressive tobacco control policies, mass media anti-tobacco use and benefit promotion campaigns, and high taxation on cigarettes at the state level have helped to drive down smoking prevalence across the state and within Medicaid. Furthermore, the state Medicaid program recently removed all priorauthorization requirements, restrictions on the number of yearly quit attempts, and restrictions on smoking cessation product formularies within the FFS and MMC programs. Evaluating the success of these new changes, and ongoing initiatives designed to increase quit attempts, is dependent on rigorous standardized measurement methodology, which is specific to this population, and repeatable over time.
Funding
This research was completed by the New York State Department of Health with partial funding from the Centers for Disease Control and Prevention cooperative agreement 5NU58DP005978, National State-Based Tobacco Control Programs.
Declaration of Interests
None declared.
